Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, ottobre 05
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Capricor Therapeutics Inc
CAPR
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$8.95
0.01
0.11%
Ult. Agg.: Oct 5, 6:22 AM
$8.91
-0.03
-0.34%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Capricor Therapeutics Financials
Capricor Therapeutics (CAPR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval
Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9 million.
Vandana Singh
Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why
Capricor Therapeutics shares surged 67.22% after hours following quarterly results and an update on the FDA review of its application.
Mohd Haider
PRO
Capricor Therapeutics Q2 EPS $(0.70) Misses $(0.58) Estimate
Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.58) by 20.69 percent. This is a 22.81 percent decrease over losses of $(0.57) per
Benzinga Newsdesk
PRO
Capricor Therapeutics Q1 EPS $(0.59) Misses $(0.50) Estimate
Benzinga Newsdesk
Earnings Scheduled For May 12, 2026
Benzinga Insights
PRO
Capricor Therapeutics Believes That, Based On The Current Operating Plan And Financial Resources, Its Available Cash, Cash Equivalents And Marketable Securities Will Be Sufficient To Cover Anticipated Expenses And Capital Requirements Through 2027
Expectation Excludes Any Additional Potential Milestone Payments Under The Commercialization And Distribution Agreements With Nippon Shinyaku, As Well As Any Strategic Use Of Capital Not Currently In The Company's Base
Benzinga Newsdesk
